A Phase 4 interventional study of Sleep Hygiene Education and Melatonin IR, 3 mg in Insomnia, Insomnia Disorder and Chronic Insomnia, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania — 3 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · University of Pennsylvania.
Among the 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania, this one has the largest planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 4, and was the 24th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →3 of the 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 55–85
University of Pennsylvania · Sites in United States
Ages 18–55 · Women only
By country, each count listing its studies:
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 36 across the 22 interventional studies, 31 across the 2 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
1 of the studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05373537University of PennsylvaniaTreatment to Improve Sleep in Caregivers With Insomnia and a Child With Autism | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).
Nearly 50% of primary care patients report symptoms of insomnia (e.g., problems initiating and/or maintaining sleep). Such sleep-related difficulties can presage new onset comorbid illness, as well as exacerbate, and be exacerbated by, existing comorbid illnesses. Accordingly, effectively treating insomnia in primary care patients is an untapped means towards the promotion of better public health.
Research Question:
While cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment, most patients (particularly those in primary care) do not have access to this form of therapy.
Instead, the majority of treated patients are using over-the-counter medications (OTCs), including melatonin and diphenhydramine (e.g., Benadryl), or are prescribed hypnotics (most commonly trazodone or zolpidem [e.g., Ambien]). Surprisingly, little is known about the absolute or relative effectiveness and safety of these commonly used medications, and of the often used medications, only Ambien is approved/recommended by the FDA and professional medical or sleep medicine societies. There are also limited data on which of these medical strategies has the best risk/benefit profile or is most acceptable to patients. The investigators' recent evaluation of FDA-approved medications for insomnia suggests doxepin, which is less commonly prescribed, has the most optimal risk/benefit profile. Multiple agencies have called for rigorous comparative effectiveness studies addressing these knowledge gaps, including the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), and the Patient-Centered Outcomes Research Institute (PCORI). Moreover, the investigators' feedback from stakeholders shows that the need for such data is not just a professional practice concern, but shared by primary care patients and clinicians. Thus, evidence-based guidance on the management of insomnia with OTC and prescriptive medications is urgently needed.
Protocol Synopsis:
The investigators propose to conduct a large-scale, double blinded, placebo-controlled sequential multiple assignment randomized trial (SMART) comparing the relative effectiveness and safety of over-the counter medications commonly used by patients to treat their insomnia (i.e., diphenhydramine and melatonin) and prescriptive medications that are either commonly prescribed by clinicians (i.e., zolpidem and trazodone) or less commonly used, but may have a more optimal risk/benefit profile (i.e., doxepin). All conditions will use a nightly dosing strategy and include sleep hygiene education. To better align with current practice, participants who tolerate an initial lower medication dose but do not exhibit a treatment response will increase to a higher dose after 2 weeks. Treatment responders at 1 month will be followed for up to 6 months to understand longer-term maintenance of treatment benefits. The SMART design will re-randomize treatment non-responders at 1 month to an alternative arm (with each successive treatment non-response), providing all participants the opportunity to secure a treatment response with one of the study medications. To maintain blinding, participants will be instructed to take each medication (including placebo) 30 minutes prior to bed and all medications will be manufactured by a central Pharmacy to appear identical. All participants will be further instructed to be in bed for a period of 7-9 hours to both promote safety and potentially increase medication effects on early morning awakening and total sleep time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Patients will be ineligible if they meet any of the following criteria: self-reported daytime napping (≥1 hour per day on ≥3 days per week); a history of suicidal attempts or current ideation, acute or chronic psychiatric or medical condition not controlled by therapy (according to their primary care physician), or current alcohol or drug misuse; or the diagnoses of (or high risk for) other sleep disorders, including circadian rhythm disorders (phase advance or phase delay syndromes), shift work related sleep disorder ("day sleepers" who work \~11pm to 7am) and those with rotating shiftwork schedules. To determine eligibility, all subjects will be screened using a multitier process including: an online screener; an intake interview; a review of the subjects EMR; and, finally, the receipt of the patient's PCP's assent. The following provides additional listing and details (AD) for the Exclusion Criteria:
General Considerations
Women's Health Given the potential for teratogenic effects with at least trazodone (FDA Class C), women intending to become pregnant, or who are pregnant, or who are breastfeeding will not be eligible for the study. Women will be asked to confirm the use of using self-report and, if applicable, by providing evidence of contraceptive medication (e.g., prescription or pill pack). We will perform a urine pregnancy test at baseline for female participants who are of reproductive age to confirm eligibility. At study enrollment, participants will be told to alert the study team and stop taking study medications if they become pregnant. Participants will be asked to test for pregnancy in the event of a missed cycle.
Medical and Psychiatric Considerations
Sleep Disorders and Sleep Habits
Medications and Concomitant meds
Lifestyle
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nightly 30 minutes prior to bed (3 or 5 mg)
Other: Sleep Hygiene Education · Dietary Supplement: Melatonin IR, 3 mg · Dietary Supplement: Melatonin IR, 5 mg
Nightly 30 minutes prior to bed
Other: Sleep Hygiene Education · Drug: Placebo
Nightly 30 minutes prior to bed (25 or 50 mg). Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.
Other: Sleep Hygiene Education · Drug: Diphenhydramine, 25 mg · Drug: Diphenhydramine, 50 mg
Nightly 30 minutes prior to bed (5 or 10 mg)
Other: Sleep Hygiene Education · Drug: Zolpidem, 5 mg · Drug: Zolpidem, 10 mg
Nightly 30 minutes prior to bed (3 or 6 mg)
Other: Sleep Hygiene Education · Drug: Doxepin, 3 mg · Drug: Doxepin, 6 mg
Nightly 30 minutes prior to bed (50 or 100 mg)
Other: Sleep Hygiene Education · Drug: Trazodone, 50 mg · Drug: Trazodone, 100 mg
Standard behavioral and environmental recommendations aimed at promoting healthy sleep
Also known as: Sleep Hygiene
Immediate release formulation of melatonin, once nightly 30 minutes prior to bed
Also known as: Acetyl-5-methoxytryptamine
Immediate release formulation of melatonin, once nightly 30 minutes prior to bed
Also known as: Acetyl-5-methoxytryptamine
Diphenhydramine 25 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.
Also known as: Benadryl
Diphenhydramine, 50 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.
Also known as: Benadryl
Doxepin, 3 mg, once nightly 30 minutes prior to bed
Also known as: Silenor
Doxepin, 6 mg, once nightly 30 minutes prior to bed
Also known as: Silenor
Trazodone, 50 mg, once nightly 30 minutes prior to bed
Also known as: Desyrel
Trazodone, 100 mg, once nightly 30 minutes prior to bed
Also known as: Desyrel
Placebo, once nightly 30 minutes prior to bed
Also known as: Inactive Drug, Inert Capsule
Zolpidem, 5 mg, once nightly 30 minutes prior to bed
Also known as: Ambien
Zolpidem, 10 mg, once nightly 30 minutes prior to bed
Also known as: Ambien
Relative treatment response rates during acute (1-month) treatment phase
Defined as an at least 8-point reduction on the Insomnia Severity Index (ISI)
Time frame: From treatment initiation to 1 month after treatment initiation
Relative safety and tolerability based on side effects during acute (1-month) treatment phase
Percent of participants who experience 1 or more side effect(s), as well as the average number of events, incidence rate, and severity of events for each medication, as assessed by self-report (spontaneous and based on a weekly medical symptoms checklist)
Time frame: From treatment initiation to 1 month after treatment initiation
Relative effects on daytime symptoms and function during acute (1-month) treatment phase
As measured by the Functional Outcomes of Sleep Questionnaire (FOSQ- 10). Min. score: 5, Max Score: 20 Lower score = more functional impairment Higher score = less functional impairment
Time frame: From treatment initiation to 1 month after treatment initiation
Durability of treatment response during longer-term maintenance (1-6 months) treatment phase
Among initial treatment responders based on Insomnia Severity Index (ISI) and tolerability, the percent of subjects who continue to exhibit an ISI-based treatment response
Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Relative safety and tolerability based on side effects during longer-term maintenance (1-6 months) phase
Among initial treatment responders based on ISI and tolerability, percent of participants who experience 1 or more side effect(s), as well as the average number of events, incidence rate, and severity of events for each medication, as assessed by self-report (spontaneous and based on a weekly medical symptoms checklist)
Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Durability of effects on daytime symptoms and function during longer-term maintenance (1-6 months) phase
Among initial treatment responders based on Insomnia Severity Index (ISI) and tolerability, the relative improvements in on the Functional Outcomes of Sleep Questionnaire (FOSQ- 10). Min. score: 5, Max Score: 20. Lower score = more functional impairment, higher score = less functional impairment
Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
Sleep Latency (SL)
Average self-reported Sleep Latency (SL), per sleep diary entries
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Wake After Sleep Onset (WASO)
Average self-reported Wake After Sleep Onset (WASO), per sleep diary entries
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Sleep Duration/Total Sleep Time (TST)
Average total sleep time (TST), calculated from daily sleep diaries
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Daytime Insomnia Symptoms
As measured by The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Min. score: 0, Max score: 140. Lower score = less daytime insomnia symptoms/impairment, Higher score = more daytime insomnia symptoms/impairment
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Daytime Sleepiness
As measured by the Epworth Sleepiness Scale (ESS) Min. score: 0, Max score: 24 Lower score = less daytime sleepiness Higher score = more daytime sleepiness
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Fatigue
As measured by the Brief Fatigue Inventory (BFI). Min. score: 0, Max score: 10. Lower score = less fatigue, higher score = more fatigue
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Depression
As measured by the Patient Health Questionnaire (PHQ-9). Min. score: 0, max score: 27. Lower score = less depression, higher score = more depression
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Anxiety
As measured by the General Anxiety Disorder-7 (GAD-7). Min. score: 0, max score: 21. Lower score = less anxiety, higher score = more anxiety
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Cognitive Dysfunction and Residual Sedation
As measured by the 90-second Digit Symbol Substitution Test (DSST). Min. score: 0, max score: 120. Lower score = more cognitive dysfunction \& residual sedation, higher score = less cognitive dysfunction \& residual sedation
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Attention/Fatigue
As measured by number of lapses and mean reaction time on a 3-minute Psychomotor Vigilance Test (PVT). Min. lapses: 0, max lapses: 45. Less lapses = better performance (better attention, less fatigue), more lapses = worse performance (worse attention, more fatigue). Min mean reaction time: 100 ms, max mean reaction time: 500 ms. Lower mean reaction time = better performance (better attention, less fatigue), higher mean reaction time = worse performance (worse attention, more fatigue)
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported Quality of Life
As measured by The 12-item Short Form Survey (SF-12) Min: 0, Max: 100 (normed to population scores). Lower score = worse quality of life, higher score = better quality of life
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Self-Reported State Alertness Versus Sleepiness
As measured by the Karolinska Sleepiness Scale (KSS), a single-item measure of state alertness versus sleepiness, administered twice daily. The item is a Likert-scale with a range of 1 (extremely alert) to 9 (very sleepy), with lower scores representing higher levels of state alertness and higher scores representing higher levels of state sleepiness.
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Sleep Continuity, Activity and Caloric Expenditure
As measured by a Fitbit, a commercially-available wearable device that utilizes movement detection and heart rate measurements to make sleep/wake assessments every 60 seconds, as well as hourly measures of heart rate, diurnal activity levels, and inferential measures of caloric expenditure.
Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)
Plan to share: Yes — Following the trial, the study's de-identified data will be made available for archival analyses (first to study site investigators and then to all interested clinical investigators) consistent with PCORI data sharing policies: "Data collected as part of this research project will be de-identified and such de-identified data to be used for secondary research purposes and shared with researchers not affiliated with the institution conducting the research project." All shared data sets will be de-identified and will only retain a code that indicates the order in which the patient was enrolled and their site of origination. PCORI must approve all sharing of information/data prior to its occurrence.
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jan 2032, 68 months after the start.
Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 68 months is above that.
Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Diphenhydramine · Doxepin · Trazodone · Zolpidem
Sleep Initiation and Maintenance Disorders →